Related Experiment Video
Updated: Mar 1, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.3K
Renin-angiotensin system blockade: Finerenone.
Luis M Ruilope1, Juan Tamargo2
1Instituto de Investigación imas, Madrid, Spain; Unidad de Hipertensión, Hospital 12 de Octubre, Departamento de Medicina Preventiva y Salud Publica, Universidad Autónoma, Avda de Cordoba s/n, 28041 Madrid, Spain; Escuela de Estudios Postdoctorales e Investigación, Universidad Europea de Madrid, Madrid, Spain.
Nephrologie & Therapeutique
|June 5, 2017
Summary
Finerenone, a novel mineralocorticoid receptor antagonist, shows promise for cardiorenal protection in preclinical and Phase II studies. Further Phase III trials are needed to confirm its clinical benefits in patients with heart failure and chronic kidney disease.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Finerenone is a novel selective nonsteroidal mineralocorticoid receptor antagonist.
- Preclinical studies suggest lower doses of finerenone achieve cardiorenal protective effects compared to spironolactone and eplerenone.
Purpose of the Study:
- To evaluate the efficacy and safety of finerenone in patients with heart failure and/or chronic kidney disease, particularly those on renin-angiotensin system inhibitors.
- To assess the drug's impact on albuminuria, hyperkalemia, and other key clinical markers.
Main Methods:
- Phase II clinical studies involving patients with heart failure, type-2 diabetes mellitus, and/or chronic kidney disease.
- Administration of finerenone to patients on renin-angiotensin system inhibitors.
Main Results:
- Finerenone demonstrated effectiveness and safety in the studied patient population.
- Significant reduction in albuminuria and a low rate of hyperkalemia were observed.
- Primary endpoints included serum potassium, estimated glomerular filtration rate, albuminuria, and N-terminal prohormone B-type natriuretic peptide levels.
Conclusions:
- Phase II findings for finerenone are encouraging, showing potential cardiorenal benefits.
- Further large-scale, long-term Phase III trials are necessary to confirm improved clinical outcomes and validate the drug's greater affinity and selectivity.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:33Hormonal Regulation
36.5K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
36.5K